Integrated Center for Advanced Medical Technology

Kochi Medical School Hospital

Prostatic Cancer

Spondylarthritis

Cardiomyopathies

Amyloidosis

Axial Spondyloarthritis

Psoriasis

Asthma

Spondylitis

Abiraterone

Prednisolone

Prednisone

Lebrikizumab

ALXN2060

Bicalutamide

Docetaxel

Enzalutamide

KHK4827

Androgen

Janssen (J&J Innovative Medicine)

Roche

Alexion Pharmaceuticals

Kyowa Kirin

condition

allSponsorName

Eidos Therapeutics

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Kochi Medical School Hospital | Integrated Center for Advanced Medical Technology

Site insights

Work at this site?

Active trials

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Trial sponsors